Accure Acne Inc., based in Boulder, Colorado, is a privately owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. “The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution. . . . The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio,” reads a recent article. “The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85% of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.”
To view the full article, visit https://ibn.fm/9F93U
About Accure Acne Inc.
Accure is committed to developing a novel and impactful solution for acne sufferers that employs a revolutionary technology designed to improve their long-term quality of life. The company, with a uniquely impressive clinical and technical team, is focused on developing a truly differentiated and protected product for clinicians worldwide. The Accure device has been granted CE Mark approval, which allows Accure to commercialize in the European Union while creating a global and exclusive intellectual property portfolio. The company is committed to developing a uniquely compelling value proposition. Accure has developed a clear and compelling go-to-market strategy, leveraging significant commercialization experience and regulatory expertise. For more information about the company, visit www.AccureAcne.com.
NOTE TO INVESTORS: The latest news and updates relating to Accure Acne are available in the company’s newsroom at https://ibn.fm/ACNE
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
